Comparable results for oral semaglutide in obesity

23 May 2023

Novo Nordisk (NOV: N) has already achieved a major breakthrough with its results with injectable semaglutide 2.4mg in obesity, a drug branded as Wegovy.

But now the Danish drugmaker has repeated the trick with once-daily oral semaglutide 50mg, which has been compared for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities in OASIS 1, a 68-week Phase IIIa trial.

On Tuesday, Novo Nordisk announced headline results. The trial achieved its primary endpoint by demonstrating a statistically-significant and superior weight loss at week 68 with oral semaglutide 50mg versus placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK